Topics

Janssen Submits sBLA for Daratumumab Combo to Treat Multiple Myeloma

19:00 EST 10 Feb 2020 | Cancer Networks

Janssen Pharmaceutical Companies submitted a supplemental biologics license application for daratumumab in combination with carfilzomib and dexamethasone to treat patients with relapsed/refractory multiple myeloma.

Original Article: Janssen Submits sBLA for Daratumumab Combo to Treat Multiple Myeloma

NEXT ARTICLE

More From BioPortfolio on "Janssen Submits sBLA for Daratumumab Combo to Treat Multiple Myeloma"

Quick Search

Relevant Topics

Biotherapeutics
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...